
Global Active Pharmaceutical Ingredients Market, By Manufacturer (Captive & Merchant), By Synthesis (Synthetic, Chemical, Biotech, Plant Extracts, High-potency & Other), By Drug (Branded or Innovative, Generic Prescription & OTC (Over-the-counter), By Therapeutic (Anti-infective, Metabolic Disorders, Cardiovascular, Respiratory Drugs) By Region (North America, Europe, Asia Pacific, Middle East & Africa and Latin America); Trend Analysis, Competitive Market Share & Forecast, 2015-2025
- Published Date: September 2019
- Report ID: BWC19271
- Available Format: PDF
- Page: 125
Report Overview
Global
Active Pharmaceutical Ingredient Market: Overview
Active Pharmaceutical Ingredient is a substance used for the
manufacturing of finished pharmaceutical product and designed to furnish
pharmacological activity or have a direct effect on the mitigation, cure,
diagnosis, and prevention of disease. In combination therapies combination of
active pharmaceutical ingredient is used to treat different symptoms via a
combination of various active pharmaceutical ingredients such as herbal
medicines integrate with several substances for the pharmacological activity on
the body.
A finished dosage form of any drug is the combination of active
pharmaceutical ingredient and excipients; Active Pharmaceutical Ingredient is
the active substances which help to deliver the medication and excipient is
chemically inactive substances such as mineral oil.
The manufacturing of active pharmaceutical ingredient is not a
single step reaction from raw material. It involves several chemical compounds.
The compound used in the manufacturing of Active Pharmaceutical ingredient from
raw material is known as Intermediate. Active Pharmaceutical Ingredient has a
significant effect on the efficacy of medications; accordingly, the quality of
the active pharmaceutical ingredient is the core of effective and safe drug
manufacturing.
Global Active Pharmaceutical Ingredient Market forecast and
Trends
Active
Pharmaceutical Ingredient Market anticipated to reach US$ 257,891 Million by
2025 with a significant CAGR of 5.97% in the forecast period of 2015-25. This is due to increasing prevalence
rate of cardiovascular and chronic diseases, hospital-acquired infections
(HAIs), and rising demand for generic drugs & usage pattern of the
biosimilar.
Patent expiry of the blockbuster drugs, growing demand of
generic medicine and rising expenses of healthcare coupled with the government
initiatives are the key factors anticipated to contribute to the market growth
of the generic segment in the active pharmaceutical industry. A lucrative
number of patents for active pharmaceutical ingredients mainly in the oncology
and other top therapeutic segment are anticipated to expire or lose patent
protection in the forecast period. Due to this, it is estimated to unlock a
significant market opportunity for the generic drug manufacturer and resulting
in the expansion of the active pharmaceutical ingredient market in the forecast
period of 2019-25.
Growth drivers
Increasing adoption of generic medicine
Increasing adoption rate of generic medicine in the developing
countries drive the global medical spending in generic drug segment. Emerging
economies such as India and China, as manufacturers have sufficient
manufacturing units, a higher spending power, and greater significance on
transparent pricing by measuring effects on the population. In the case of drug
manufacturing, mid-size manufacturing companies cannot fund the expenses of developing
and marketing a new drug which is the key factor for shifting market trend
towards generic drugs. In comparison with brand name analogue, the prices of
generic drugs are cheaper with the same standards followed by innovator drug
such as safety, efficacy, and quality which is the key factor for driving
growth of Active Pharmaceutical Ingredient market in the forecast period
2019-25.
Growing demand for CVD drugs
The Active Pharmaceutical Ingredient market is getting a boost
from the growing prevalence of cardiovascular, chronic, and infectious diseases
coupled with the increasing trend of an unhealthy lifestyle and growing
geriatric population. CVD is emerging as the lucrative therapeutic segment for
innovative and generic drug manufacturing companies in terms of CVD drug
consumption by end-users in the forecast duration.
Restraints
Huge Investment and Increasing Competition
The increasing rate of a small manufacturer in the field of
niche APIs has resulted in a highly stiff competition across the globe. For the
manufacturing companies, the main concern is production setup of active
pharmaceutical ingredient, which required immense capital investment. The
strict policy and reforms by different government authorities across the globe
are also causing hindrance. Innovative advancement in the complex Active
Pharmaceutical Ingredient coupled with monitory and manufacturing investment
anticipated to hamper the Active Pharmaceutical Ingredient market in the coming
years.
Global Active Pharmaceutical Ingredient Market: Synthesis Type
Based on the synthesis type the Active Pharmaceutical;
Ingredient market segmented into synthetic, biotech (monoclonal antibodies,
recombinant proteins, vaccines, and others), plant extract, high potency, and
classical fermented Active Pharmaceutical Ingredients. Availability of
innovative drug and technology propel the biotech synthesis of Active
Pharmaceutical Ingredient segment in the global market.
Global Active Pharmaceutical Ingredient Market: Therapeutic Area
Based on therapeutic area segmentation, the market is bifurcated into anti-infective, cardiovascular, oncology, respiratory, central nervous, and metabolic disorders drugs. Increasing prevalence of cardiovascular conditions, chronic and infectious diseases anticipated to witness the growth of oncology in the upcoming years.
Global Active Pharmaceutical Ingredient Market: Drug Type
On the basis of drug type, the market is segmented into generic
drug, OTC (over the counter) drug and branded drug. Increasing demand for the
low cost of generic drug coupled with key therapeutic application segment the
generic prescription market is anticipated to witness a lucrative growth rate
in the coming years. Regulated policy and reforms by the United States to
improve the affordability of healthcare is one of the key factor responsible
for the boom of generic product in the market.
Global Active Pharmaceutical Ingredient Market: Manufacturer
Type
In terms of manufacturer type, the market is segmented into captive
(In-house) manufacturer and merchant (contract) manufacturer. Due to the
economic benefits and prevent technology leakage followed by the trend of
maintaining Active Pharmaceutical Ingredient Manufacturing with the integration
in pharmaceutical supply chain propel the growth of captive (In-house)
manufacturers in the forecast period.
Global Active Pharmaceutical Ingredient Market: Regional
insights
North America is anticipated to dominate the active pharmaceutical ingredient market over the forecast period of 2019-25. Advancement in technology and in-process R&D of innovative drug with the increasing incidence rate of diseases coupled with the prominent player in the region is the significant factor driving the growth of North American Active Pharmaceutical Ingredient market. Europe marked the significant growth in the global active pharmaceutical ingredient market backed by initiative enhancement within the region that provide balance in the development of generic drugs.
Active
pharmaceutical ingredient Market: Competitive Landscape
Some of the major industry players are Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sun Pharmaceutical Industries Ltd., Pfizer Inc., Aurobindo Pharma, Abbott Laboratories, Boehringer Ingelheim International GmbH, Merck & Co., Inc., Novartis AG, Hoffmann-La Roche Ltd, Bayer AG and Other Prominent Players
The objective of the Study:
To analyze and forecast the
global Active Pharmaceutical Ingredient market size of the market, in terms of
value.
To examine the careful
market segmentation and forecast the market size, in terms value, based on the
region by segmenting the Global Active Pharmaceutical Ingredient market into
five regions, namely, North America, Europe, Asia Pacific, Middle East, South
America and their leading countries.
To outline, categorized and
forecast the global Active Pharmaceutical Ingredient market based on the
product type, application and end user.
To examine competitive
developments like technological advancement, services, and regulative framework
within the global Active Pharmaceutical Ingredient Market.
To highlight the impact
analysis of the factors, affecting the market dynamics such as drivers,
restraints, opportunities, and challenges.
To strategically profile the
key players and comprehensively analyze their market shares along with
detailing the competitive landscape for market leaders.
Scope of the Report
By Manufacturer
·
Captive
(In-house)
API Manufacturing
·
Merchant
(Contract) API Manufacturing
By API (Active Pharmaceutical Ingredient) Type
·
Synthetic Chemical API
·
Biotech/Biological API
·
Plant Extracts API
·
High-potency API
·
Classical Fermentation API
By Drug
·
Branded or Innovative Prescription Drugs
·
Generic Prescription Drugs
·
over-the-counter (OTC) Drugs
·
Others
By Therapeutic Area
·
Anti-infective Drugs
·
Metabolic Disorders Drugs
·
Cardiovascular Drugs
·
Oncology Drugs
·
Central Nervous System Drugs
·
Respiratory Diseases Drugs
·
Other
By Region:
•
North America
•
Europe
•
Asia Pacific (APAC)
•
Latin America
•
Middle East & Africa
Business Questions answer by the report
•
How will the market drivers, restraints and opportunities affect
the market dynamics?
•
What will be the market size in terms of value and volume and
market statistics with a detailed classification?
•
Which segment dominates the market or region and one will be the fastest
growing and why?
•
A comprehensive survey of the competitive landscape and the market
participant players
•
Analysis of strategy adopted by the key player and their impact on
other players.
Customization Scope for the Client
Client
satisfaction is our first and last priority and that’s why BlueWeave Consulting
offers customization according to Company’s specific needs. The following
customization options are available for the report:
Additional Company Information
·
With five additional company detail analysis
·
Additional country analysis
· Detailed segment analysis
1. Research Framework
1.1. Research
Objective
1.2. Product
Overview
1.3. Market
Segmentation
2. Research Methodology
2.1. Qualitative
Research
2.1.1.
Primary & Secondary Sources
2.2. Quantitative
Research
2.2.1.
Primary & Secondary Sources
2.3. Breakdown
of Primary Research Respondents, By Region
2.3.1.
Secondary Research
2.3.2.
Primary Research
2.4. Breakdown
of Primary Research Respondents
2.5. Market
Size Estimation
2.6. Assumption
for the Study
2.7. Market
Breakdown & Data Triangulation
3. Executive Summary
4. Global Active Pharmaceutical
Ingredient Industry Insights
4.1. Industry
Value Chain Analysis
4.1.1.
Vendor Matrix
4.2. DROC
Analysis
4.2.1.
Growth Drivers
4.2.2.
Restraints
4.2.3.
Opportunities
4.2.4.
Challenges
4.3. Technological
Landscape
4.4. Regulatory
Framework
4.5. Company
market share analysis,2018
4.6. Porter’s
Five forces analysis
4.6.1.
Bargaining Power of Suppliers
4.6.2.
Bargaining Power of Buyers
4.6.3.
Threat of New Entrants
4.6.4.
Threat of Substitutes
4.6.5.
Intensity of Rivalry
4.7. PESTEL
Analysis
4.8. Strategic
Outlook
5. Global Active Pharmaceutical
Ingredient Market Overview
5.1. Market
Size & Forecast 2015-2025
5.1.1.
By Value (USD)
5.2. Market
Share & Forecast
5.2.1.
By Manufacturer Type
5.2.1.1.
Captive (In-House) Manufacturer
5.2.1.2.
Merchant (Contract) Manufacturer
5.2.2.
By Active Pharmaceutical Ingredient Type
5.2.2.1.
Synthetic Chemical API
5.2.2.2.
Biotech/Biological API
5.2.2.3.
Plant Extracts API
5.2.2.4.
High-potency API
5.2.2.5.
Classical Fermentation API
5.2.3.
By Drug Type
5.2.3.1.
Branded or Innovative Drug
5.2.3.2.
Generic Prescription Drug
5.2.3.3.
OTC (over the counter) Drug
5.2.3.4.
Other Drug
5.2.4.
By Therapeutic Area
5.2.4.1.
Anti-Infective Drug
5.2.4.2.
Metabolic Disorders Drug
5.2.4.3.
Cardiovascular Drug
5.2.4.4.
Oncology Drug
5.2.4.5.
Central Nervous System Drug
5.2.4.6.
Respiratory Drug
5.2.4.7.
Other Therapeutic Drug
5.2.5.
By Region
5.2.5.1.
North America
5.2.5.2.
Europe
5.2.5.3.
Asia Pacific
5.2.5.4.
Latin America
5.2.5.5.
Middle East & Africa
6. North America Active Pharmaceutical
Ingredient Market
6.1. Key
Regional Trends
6.2. Market
estimates & forecast
6.2.1.
By Manufacturer Type
6.2.2.
By Active Pharmaceutical Ingredient Type
6.2.3.
By Drug Type
6.2.4.
By Therapeutic Area
6.2.5.
By Country
6.2.5.1.
U.S
6.2.5.2.
Canada
7. Europe Active Pharmaceutical
Ingredient Market
7.1. Key
Regional Trends
7.2. Market
estimates & forecast
7.2.1.
By Manufacturer Type
7.2.2.
By Active Pharmaceutical Ingredient Type
7.2.3.
By Drug Type
7.2.4.
By Therapeutic Area
7.2.5.
By Country
7.2.5.1.
Germany
7.2.5.2.
U.K
7.2.5.3.
France
7.2.5.4.
Italy
7.2.5.5.
Rest of Europe
8. Asia Pacific Active Pharmaceutical
Ingredient Market
8.1. Key
Regional Trends
8.2. Market
estimates & forecast
8.2.1.
By Manufacturer Type
8.2.2.
By Active Pharmaceutical Ingredient Type
8.2.3.
By Drug Type
8.2.4.
By Therapeutic Area
8.2.5.
By Country
8.2.5.1.
China
8.2.5.2.
India
8.2.5.3.
Japan
8.2.5.4.
Rest of APAC
9. Latin America Active Pharmaceutical
Ingredient Market
9.1. Key
Regional Trends
9.2. Market
estimates & forecast
9.2.1.
By Manufacturer Type
9.2.2.
By Active Pharmaceutical Ingredient Type
9.2.3.
By Drug Type
9.2.4.
By Therapeutic Area
9.2.5.
By Country
9.2.5.1.
Brazil
9.2.5.2.
Argentina
9.2.5.3.
Rest of Latin America
10. Middle East & Africa Active
Pharmaceutical Ingredient Market
10.1.
Key Regional Trends
10.2.
Market estimates & forecast
10.2.1. By
Manufacturer Type
10.2.2. By
Active Pharmaceutical Ingredient Type
10.2.3. By
Drug Type
10.2.4. By
Therapeutic Area
10.2.5. By
Country
10.2.5.1.
Saudi Arabia
10.2.5.2.
UAE
10.2.5.3.
South Africa
10.2.5.4.
Rest of MEA
11. Company Profile (Company Overview,
Financial Matrix, Key Product landscape, Key Personnel, Key Competitors,
Contact Address, and Strategic Outlook)*
11.1.
Teva Pharmaceutical Industries Ltd.
11.2.
Boehringer Ingelheim GmbH
11.3.
Sun Pharmaceutical Industries Ltd.
11.4.
Pfizer Inc.
11.5.
Aurobindo Pharma
11.6.
Abbott Laboratories
11.7.
Merck & Co., Inc.
11.8.
Novartis AG
11.9.
Hoffmann-La Roche Ltdss
11.10.
Bayer AG
11.11.
Other Prominent Players
*Financial
Details Not Be Captured in Case of Unlisted Companies
**The segmentation and the
companies
Market Segmentation
To request a free sample copy of this report, please complete the form below.
We value your investment and offer free customization with every report to fulfil your exact research needs.
RELATED REPORTS
WHY CHOOSE US
-
24/7 Research support
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
-
Coustom Research Service
Ask the Analyst to customize an exclusive study to serve your research needs
-
Quality & Accuracy
Ask the Analyst to customize an exclusive study to serve your research needs
-
Data Visualization
As the business world is changing dynamically every day. We need to stay pin point in relation to data management and optimum data utilization
-
Information security
We never share your personal and confidential information. Your personal information is safe and secure with us.